These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36142566)

  • 21. Neuronal cyclin-dependent kinase 5: role in nervous system function and its specific inhibition by the Cdk5 inhibitory peptide.
    Kesavapany S; Li BS; Amin N; Zheng YL; Grant P; Pant HC
    Biochim Biophys Acta; 2004 Mar; 1697(1-2):143-53. PubMed ID: 15023357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New approaches to the discovery of cdk5 inhibitors.
    Glicksman MA; Cuny GD; Liu M; Dobson B; Auerbach K; Stein RL; Kosik KS
    Curr Alzheimer Res; 2007 Dec; 4(5):547-9. PubMed ID: 18220519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of small molecules against cyclin dependent kinase-5 using chemoinformatics approach for Alzheimer's disease and other tauopathies.
    Shukla R; Singh TR
    J Biomol Struct Dyn; 2022 Apr; 40(6):2815-2827. PubMed ID: 33155527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An unusual member of the Cdk family: Cdk5.
    Dhariwala FA; Rajadhyaksha MS
    Cell Mol Neurobiol; 2008 May; 28(3):351-69. PubMed ID: 18183483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclin-dependent kinase five mediates activation of lung xanthine oxidoreductase in response to hypoxia.
    Kim BS; Serebreni L; Fallica J; Hamdan O; Wang L; Johnston L; Kolb T; Damarla M; Damico R; Hassoun PM
    PLoS One; 2015; 10(4):e0124189. PubMed ID: 25831123
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of Human Dihydroorotate Dehydrogenase Inhibitor by a Pharmacophore-Based Virtual Screening Study.
    Galati S; Sainas S; Giorgis M; Boschi D; Lolli ML; Ortore G; Poli G; Tuccinardi T
    Molecules; 2022 Jun; 27(12):. PubMed ID: 35744791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Negative regulation of cyclin-dependent kinase 5 targets by protein kinase C.
    Sahin B; Hawasli AH; Greene RW; Molkentin JD; Bibb JA
    Eur J Pharmacol; 2008 Mar; 581(3):270-5. PubMed ID: 18190909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism of CDK5/p25 binding by CDK inhibitors.
    Mapelli M; Massimiliano L; Crovace C; Seeliger MA; Tsai LH; Meijer L; Musacchio A
    J Med Chem; 2005 Feb; 48(3):671-9. PubMed ID: 15689152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitors.
    Rzasa RM; Kaller MR; Liu G; Magal E; Nguyen TT; Osslund TD; Powers D; Santora VJ; Viswanadhan VN; Wang HL; Xiong X; Zhong W; Norman MH
    Bioorg Med Chem; 2007 Oct; 15(20):6574-95. PubMed ID: 17697781
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent advances in understanding the roles of Cdk5 in synaptic plasticity.
    Lai KO; Ip NY
    Biochim Biophys Acta; 2009 Aug; 1792(8):741-5. PubMed ID: 19442718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of Cdk5 in cognition and neuropsychiatric and neurological pathology.
    Barnett DG; Bibb JA
    Brain Res Bull; 2011 Apr; 85(1-2):9-13. PubMed ID: 21145377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of the Inhibitory Elements in the p5 Peptide Fragment of the CDK5 Activator, p35, CDKR1 Protein.
    Binukumar BK; Shukla V; Amin ND; Bhaskar M; Skuntz S; Steiner J; Winkler D; Pelech SL; Pant HC
    J Alzheimers Dis; 2015; 48(4):1009-17. PubMed ID: 26444778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of quinolin-2(1H)-one derivatives as potent CDK5 inhibitors.
    Zhong W; Liu H; Kaller MR; Henley C; Magal E; Nguyen T; Osslund TD; Powers D; Rzasa RM; Wang HL; Wang W; Xiong X; Zhang J; Norman MH
    Bioorg Med Chem Lett; 2007 Oct; 17(19):5384-9. PubMed ID: 17709247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extraneuronal activities and regulatory mechanisms of the atypical cyclin-dependent kinase Cdk5.
    Arif A
    Biochem Pharmacol; 2012 Oct; 84(8):985-93. PubMed ID: 22795893
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclin-dependent kinase 5-mediated phosphorylation of CHIP promotes the tAIF-dependent death pathway in rotenone-treated cortical neurons.
    Kim C; Lee J; Ko YU; Oh YJ
    Neurosci Lett; 2018 Jan; 662():295-301. PubMed ID: 29111393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biological functions of CDK5 and potential CDK5 targeted clinical treatments.
    Shupp A; Casimiro MC; Pestell RG
    Oncotarget; 2017 Mar; 8(10):17373-17382. PubMed ID: 28077789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclin dependent kinase 5: A novel avenue for Alzheimer's disease.
    Bhounsule AS; Bhatt LK; Prabhavalkar KS; Oza M
    Brain Res Bull; 2017 Jun; 132():28-38. PubMed ID: 28526617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroprotective Mechanisms Mediated by CDK5 Inhibition.
    Mushtaq G; Greig NH; Anwar F; Al-Abbasi FA; Zamzami MA; Al-Talhi HA; Kamal MA
    Curr Pharm Des; 2016; 22(5):527-34. PubMed ID: 26601962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Designing of dual inhibitors for GSK-3β and CDK5: Virtual screening and in vitro biological activities study.
    Xie H; Wen H; Zhang D; Liu L; Liu B; Liu Q; Jin Q; Ke K; Hu M; Chen X
    Oncotarget; 2017 Mar; 8(11):18118-18128. PubMed ID: 28179579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Emerging Role of Cdk5 in Cancer.
    Pozo K; Bibb JA
    Trends Cancer; 2016 Oct; 2(10):606-618. PubMed ID: 27917404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.